MedTrace Logo

Study of Memantine to Treat Huntington's Disease

NCT00652457 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

To determine if memantine in doses of 10 mg BID affects memory, cognition, and behavior in patients with Huntington's disease (HD).

Conditions

Interventions

DRUG

Memantine

10 mg BID x 3 months

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Jody Corey-Bloom, MD, PhD

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-23
Primary Completion
2009-10-28
Completion
2009-10-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652457 on ClinicalTrials.gov